Alembic Pharma Karakhadi facility successfully completes USFDA inspection
Alembic Pharma Karakhadi facility successfully completes USFDA inspection
Vadodara: Alembic Pharma has announced that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its API-III Facility located at Karakhadi.
"This was a scheduled GMP inspection and was successfully completed without any Form 483 observation," the Company stated in a BSE filing.
The inspection was conducted from 17th March, 2025 to 21st March, 2025.
Read also: Alembic Global Holding incorporates wholly-owned subsidiary in USA
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Read also: Alembic Pharma bags USFDA final approval for schizophrenia drug Brexpiprazole
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.